Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axis
Shu, C.; Jin, R.; Niu, Q.; Cicka, D.; Doyle, S.; Wahafu, A.; Fan, D.; Zheng, X.; Du, Y.; Ivanov, A.; Doxie, D.; Dhodapkar, K.; Carlisle, J.; Owonikoko, T.; Ramalingam, S.; Sica, G.; Dhodapkar, M.; Zhou, W.; Mo, X.; Fu, H.
Show abstract
Harnessing the power of the immune system to treat cancer has become a core clinical approach. However, rewiring of intrinsic circuitry enables tumor cells to escape immune attacks, leading to therapeutic failure. Pharmacological strategies to reverse tumor genotype-dictated therapeutic resistance are urgently needed to advance precision immunotherapy. Here, we identify antagonists of Inhibitor of Apoptosis Protein (IAP) as potent sensitizers that restore immune-dependent killing of LKB1-mutant lung cancer cells. Mechanistic studies reveal an LKB1-IAP-JAK trimolecular complex that bridges the LKB1-mutant genotype with IAP-dependency and a STING-deficiency-mediated immune resistance phenotype. Ultimately, inhibition of IAP re-establishes JAK-regulated STING expression and DNA sensing pathway as well as enhanced cytotoxic immune cell infiltration and selective immune-dependent anti-tumor activity in an LKB1-mutant immune-competent mouse model. Thus, IAP-JAK-modulatory strategies, like IAP inhibitors, offer promising immunotherapy adjuvants to re-establish the responsiveness of "immunologically-cold" LKB1-mutant tumors to immune checkpoint inhibitors or STING-directed therapies.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response 95%
- ORMDL3 restrains type-I interferon signaling and anti-tumor immunity by promoting RIG-I degradation 95%
- VPS9D1-AS1 overexpression amplifies intratumoral TGF-β signaling and promotes tumor cell escape from CD8+ T cell killing in colorectal cancer 95%
Similar papers in this journal
- Regulatory T cells crosstalk with tumor and endothelium through lymphotoxin signaling 96%
- Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 96%
- Targeting PRMT3 Impairs Methylation and Oligomerization of HSP60 to Boost Anti-Tumor Immunity by Activating cGAS/STING Signaling 95%
Similar papers in this journal
- The RNA m6A reader YTHDF2 controls NK cell anti-tumor and anti-viral immunity 95%
- SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors 94%
- Breast cancer progression and metastasis to lymph nodes reveals cancer cell plasticity and MHC class II-mediated immune regulation 94%
Similar papers in this journal
- Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells 94%
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 94%
- ADAR1 editing dependency in triple-negative breast cancer 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.